Industry Insights

Trial inclusion begins with examining who can realistically take part

A practical framework for identifying access barriers and broadening research conversations without tokenism or unsupported claims.

Adults arriving at a welcoming clinical research information session.

Who can realistically participate in a clinical trial depends on more than who sees an advertisement. Eligibility criteria, location, visit schedules, language access, costs, referral patterns, and confidence in the research process all shape the available opportunity.

A useful inclusion effort examines these factors directly. It does not assume that a single community has one opinion about research, or treat people as representatives of a demographic category rather than individuals making their own decisions.

Start with the study question and population

The study's scientific purpose and protocol define the population being studied. Sites should understand these requirements and identify questions about criteria that may create practical barriers. Concerns can be raised with the sponsor through the appropriate process; site staff should not informally waive eligibility requirements.

Assess which people the site's ordinary referral pathways tend to reach and which they may miss. A database reflects who has interacted with the organization, not necessarily everyone who could be relevant to a research question.

Avoid presenting a site's local patient mix as proof that a trial will be representative. Actual participation also depends on interest, eligibility, accessibility, and the study's design.

Examine barriers one step at a time

Map the path from learning about the study to attending the first visit. Ask whether recruitment information is understandable, whether people can contact the site in a language they use comfortably, whether callbacks happen at workable times, and whether the visit location can be reached.

Then examine what happens after the first conversation. A person may understand the study and still be unable to take time away from work. Another may have transport but need to discuss caregiving responsibilities. These are different problems and require different responses.

Do not infer the reason for nonparticipation from a person's background. Ask respectfully where appropriate, accept that a person may not wish to explain, and record only information the organization has a legitimate reason to use.

Build relationships without borrowing trust

Community organizations and clinicians can help researchers understand local questions. Their involvement should not be presented as an endorsement unless that is accurate and authorized. Community engagement is a conversation, not permission to contact everyone associated with an organization.

Explain the study's purpose, the difference between research and usual care, and the voluntary nature of participation. Make room for critical questions and for people who decide research is not right for them.

Where outreach or referral arrangements are proposed, review privacy, consent, recruitment material, and other applicable requirements before exchanging identifiable information.

Measure access carefully

Useful operational measures may include language support requests, time to return inquiries, availability of screening appointments, and reasons people voluntarily share for declining. Select measures because they guide an action, not because they make a report look comprehensive.

Demographic information can be sensitive. Use appropriate self-reported information where permitted and relevant; do not infer race, ethnicity, or other identities from names, appearance, or neighborhoods. Limit access and avoid publishing small groups that could identify people.

A difference in conversion rates is a signal for investigation. It is not proof that the cause is motivation, trust, discrimination, or any other single factor. The protocol, stage definitions, sample size, and practical circumstances all matter.

Give the team a useful next action

An inclusion review should end with a specific operational decision: verify translated materials, expand permitted callback availability, document travel instructions, or raise a protocol burden with the sponsor. Assign an owner and review whether the action addressed the observed problem.

Do not set informal demographic targets that conflict with eligibility or encourage pressure. Follow the study's applicable recruitment plan and obligations, and seek qualified guidance for regulatory questions.

The barriers guide offers a broader journey review. The patient participation guide supports a clear, individual conversation about whether a particular opportunity makes sense.

Sources & further reading

  1. FDA: Clinical Trial Participation
  2. FDA: Informed Consent guidance
  3. FDA: E6(R3) Good Clinical Practice
About this guidance

Educational information, not medical advice or a study-specific compliance determination. This article is not represented as independently clinically reviewed. Images are editorial illustrations.

KEEP YOUR PERSPECTIVE GROWING

Continue reading.